ConductScience.org, home

Paper23429381

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

Mira JA and 15 others. Clin Infect Dis, 2013. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Papers, record 23429381. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23429381

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
2.35
iCite
Revised in PubMed
2018-12-02
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mira JAJosé A
2Rivero-Juárez AAntonio
3López-Cortés LFLuis F
4Girón-González JAJosé A
5Téllez FFrancisco
6de los Santos-Gil IIgnacio
7Macías JJuan
8Merino DDolores
9Márquez MManuel
10Ríos-Villegas MJMaría J
11Gea IIsabel
12Merchante NNicolás
13Rivero AAntonio
14Torres-Cornejo AAlmudena
15Pineda JAJuan A
16Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades InfecciosasGroup

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
HIV InfectionsMajor topic
Hepatitis CMajor topic
Interferon-alphaMajor topic
Liver CirrhosisMajor topic
Polyethylene GlycolsMajor topic
RibavirinMajor topic
Adult
Female
Hepacivirus
Humans
Kaplan-Meier Estimate
Liver Failure
Male
Middle Aged
Multivariate Analysis
Prospective Studies
Recombinant Proteins

Source PubMed

Download CSV of topics

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
39970137Influence of Cellular Aging on Liver Stiffness in Patients With Hepatitis C Virus Achieving Sustained Viral Response.J Infect Dis2025https://conductscience.org/library/papers/39970137PubMed
36526593Evaluation of treatment access and scope of a multistate hepatitis C virus Extension for Community Healthcare Outcomes telehealth service in the US Indian Health System, 2017-2021.J Rural Health2023https://conductscience.org/library/papers/36526593PubMed
35646260Revolution in the diagnosis and management of hepatitis C virus infection in current era.World J Hepatol2022https://conductscience.org/library/papers/35646260PubMed
35126840Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.World J Hepatol2022https://conductscience.org/library/papers/35126840PubMed
35030279HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.Hepatology2022https://conductscience.org/library/papers/35030279PubMed
33822285
Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
Eur J Clin Microbiol Infect Dis2021https://conductscience.org/library/papers/33822285PubMed
31434968Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.Sci Rep2019https://conductscience.org/library/papers/31434968PubMed
30682180Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.PLoS One2019https://conductscience.org/library/papers/30682180PubMed
30215672Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Clin Infect Dis2018https://conductscience.org/library/papers/30215672PubMed
30209336Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.Sci Rep2018https://conductscience.org/library/papers/30209336PubMed
30075765
Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
BMC Infect Dis2018https://conductscience.org/library/papers/30075765PubMed
29467555Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.World J Gastroenterol2018https://conductscience.org/library/papers/29467555PubMed
29299684Treatment of hepatitis C in special populations.J Gastroenterol2018https://conductscience.org/library/papers/29299684PubMed
29098647Current and future challenges in HCV: insights from an Italian experts panel.Infection2018https://conductscience.org/library/papers/29098647PubMed
28294492High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.HIV Med2017https://conductscience.org/library/papers/28294492PubMed
28210927Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.Hepatol Int2017https://conductscience.org/library/papers/28210927PubMed
28160269Infections in Cancer Patients with Solid Tumors: A Review.Infect Dis Ther2017https://conductscience.org/library/papers/28160269PubMed
27787664Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.Eur J Clin Microbiol Infect Dis2017https://conductscience.org/library/papers/27787664PubMed
27272121Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.Eur J Clin Microbiol Infect Dis2016https://conductscience.org/library/papers/27272121PubMed
27241060HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy.Pharmacogenomics J2017https://conductscience.org/library/papers/27241060PubMed

See all 36 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23429381

GET https://conductscience.org/api/papers/v1/23429381/cited_by?page=2